EHS
EHS

Prostate cancer: New drug for aggressive, resistant cases

Enzalutamide reduced metastasis or death risk by 71 percent in phase III trial of castration-resistant nonmetastatic prostate cancer with escalating PSA.
EHS
Back to top button